NCT05626712 - Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Type 1 DiabetesDiabetes Mellitus, Type 1

Interventions

BIOLOGICAL

CELZ-201 Administration

Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.

OTHER

Control Group

Enhanced standard of care for Type 1 Diabetes treatment only.

Trial Locations (1)

33136

RECRUITING

Diabetes Research Institute, University of Miami Miller School of Medicine, Miami